Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMDW) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Revolution Medicines (RVMDW) over the last 7 years, with Q3 2025 value amounting to -$207.3 million.

  • Revolution Medicines' Cash from Operations fell 5895.77% to -$207.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$761.8 million, marking a year-over-year decrease of 4114.88%. This contributed to the annual value of -$557.4 million for FY2024, which is 5900.76% down from last year.
  • As of Q3 2025, Revolution Medicines' Cash from Operations stood at -$207.3 million, which was down 5895.77% from -$221.8 million recorded in Q2 2025.
  • Revolution Medicines' 5-year Cash from Operations high stood at -$34.1 million for Q2 2021, and its period low was -$221.8 million during Q2 2025.
  • For the 5-year period, Revolution Medicines' Cash from Operations averaged around -$100.2 million, with its median value being -$67.1 million (2023).
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 1310.91% in 2023, then tumbled by 15734.48% in 2024.
  • Quarter analysis of 5 years shows Revolution Medicines' Cash from Operations stood at -$39.3 million in 2021, then plummeted by 57.36% to -$61.8 million in 2022, then crashed by 95.12% to -$120.6 million in 2023, then dropped by 14.7% to -$138.3 million in 2024, then crashed by 49.91% to -$207.3 million in 2025.
  • Its Cash from Operations was -$207.3 million in Q3 2025, compared to -$221.8 million in Q2 2025 and -$194.4 million in Q1 2025.